Objective HCV is intimately linked with the liver lipid metabolism, devoted to the efflux of triacylglycerols stored in lipid droplets (LDs) in the form of triacylglycerol-rich very-low-density lipoproteins (VLDLs): (i) the most infectious HCV particles are those of lowest density due to association with triacylglycerol-rich lipoproteins and (ii) HCV-infected patients frequently develop hepatic steatosis (increased triacylglycerol storage). The recent identification of lysophosphatidylcholine acyltransferase 1 (LPCAT1) as an LD phospholipid-remodelling enzyme prompted us to investigate its role in liver lipid metabolism and HCV infectious cycle. Design Huh-7.5.1 cells and primary human hepatocytes (PHHs) were infected with JFH1-HCV. LPCAT1 depletion was achieved by RNA interference. Cells were monitored for LPCAT1 expression, lipid metabolism and HCV production and infectivity. The density of viral particles was assessed by isopycnic ultracentrifugation. Results Upon HCV infection, both Huh-7.5.1 cells and PHH had decreased levels of LPCAT1 transcript and protein, consistent with transcriptional downregulation. LPCAT1 depletion in either naive or infected Huh-7.5.1 cells resulted in altered lipid metabolism characterised by LD remodelling, increased triacylglycerol storage and increased secretion of VLDL. In infected Huh-7.5.1 cells or PHH, LPCAT1 depletion increased production of the viral particles of lowest density and highest infectivity. Conclusions We have identified LPCAT1 as a modulator of liver lipid metabolism downregulated by HCV, which appears as a viral strategy to increase the triacylglycerol content and hence infectivity of viral particles. Targeting this metabolic pathway may represent an attractive therapeutic approach to reduce both the viral titre and hepatic steatosis.
INTRODUCTION
The HCV is a leading cause of chronic liver disease worldwide. Unique to this human hepatotropic virus is its tight link with the host lipid metabolism. [1] [2] [3] Clinical evidence in chronically infected patients has long recognised the high prevalence of liver steatosis, defined as an accumulation of lipids, essentially accounted for by triacylglycerols (TAGs), in cytosolic lipid droplets (LDs) of hepatocytes. Moreover, HCV particles are heterogeneous in the circulating blood of patients and the most infectious viral particles are those of exceptionally low buoyant density due to their association with apolipoprotein (Apo) B-containing TAG-rich
Significance of this study
What is already known on this subject?
▸ The most infectious HCV particles circulate as hybrid lipo-viro-particles (LVPs) consisting of viral and very-low-density lipoprotein (VLDL) components. ▸ The human hepatocyte is both the cell specialised in the biogenesis of VLDLs and the primary replication site of HCV, but whether the VLDL pathway is usurped for LVP morphogenesis is still a matter of debate. ▸ Besides the existence of LVPs another clinical feature that links HCV infection with the host lipid metabolism is the high prevalence of liver steatosis, but whether these facts are related is unknown.
What are the new findings?
▸ Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is identified as a modulator of the liver lipid homeostasis downregulated by HCV. ▸ LPCAT1 depletion increases LVP production, supporting the idea that HCV indeed hijacks the hepatocellular lipid metabolism for the benefit of highly infectious LVP morphogenesis. ▸ LPCAT1 depletion also increases VLDL secretion, suggesting that at least some of the mechanisms of LVP morphogenesis and VLDL biogenesis are shared. ▸ LPCAT1 depletion also causes steatosis, illustrating a possible link between LVP morphogenesis and liver steatosis.
How might it impact on clinical practice in the foreseeable future?
▸ Our findings designate the LPCAT1-regulated lipid metabolism pathway as an attractive host target for antiviral therapy in most difficult-to-treat patients. ▸ Compared with other lipid-modulating antiviral approaches expected to aggravate liver steatosis, targeting the LPCAT1-regulated pathway would reduce liver steatosis besides reducing HCV infectious titre.
lipoproteins in original structures referred to as lipo-viro-particles (LVPs). 4 5 As hepatocytes are specialised in the assembly and secretion of the ApoB-containing TAG-rich lipoproteins known as very-low-density lipoproteins (VLDLs), a working hypothesis is that LVPs are formed originally within infected cells, the hepatocellular lipid metabolism being hijacked by HCV for the benefit of their morphogenesis. [6] [7] [8] LDs consist of a core of TAGs and cholesterol esters surrounded by a monolayer of phospholipids (PLs) and cholesterol. 9 Importantly, TAGs stored in cytosolic LDs of hepatocytes provide most of the TAGs present in VLDLs through a mechanism of hydrolysis re-esterification. 10 11 Many proteins interact with the LD surface, as shown by proteomic characterisation of LDs isolated from hepatic cells. 12 13 The LD proteome includes structural proteins, perilipins, and proteins that control several cellular pathways including lipid metabolism (eg, lipases, acyltransferases), membrane trafficking, signalling, etc. 14 15 The interaction of these proteins with the LD surface can be modulated through mechanisms, probably of multiple causes, that are only just starting to be clarified. 16 17 Because of the large variety of PLs conferring different physicochemical properties to the LD surface, the nature of PLs is a factor that can modulate the strength of protein association. 18 19 The most abundant PL of the LD surface is phosphatidylcholine. 20 The lysophosphatidylcholine acyltransferase (LPCAT) family consists of PLremodelling enzymes, 21 among which LPCAT1 and LPCAT2 localise partially to the LD surface where they can synthesise phosphatidylcholine. 22 Moreover, LPCAT1 and LPCAT3, both expressed in hepatocytes, were recently reported to influence lipoprotein secretion from these cells. 23 24 These considerations prompted us to examine the hypothesis of a potential hijacking of LPCAT-mediated metabolism by HCV. Indeed, LPCAT1 is shown here to be downregulated by HCV. LPCAT1 depletion, in turn, was found to increase the virus infectivity.
MATERIALS AND METHODS Cell culture, infection and gene silencing
Huh-7.5.1 cells and primary human hepatocytes (PHHs) were inoculated with JFH1-HCV at a multiplicity of infection of 0.2 and 2 focus-forming units (ffu)/cell, respectively, as described previously. 25 26 Further details for infection and for transfection with HCV subgenomic replicon or core-encoding plasmid are given in the online supplementary material. ShRNA-mediated and siRNA-mediated gene silencing was used to achieve LPCAT1 depletion in Huh-7.5.1 cells and PHH, respectively (see online supplementary material).
Gene expression and virological analyses
For details of quantitative reverse-transcription real-time PCR (RT-qPCR), western blotting, confocal microscopy, Apo quantification and virological analyses, [25] [26] [27] see online supplementary material. All analyses were done at day 3 post inoculation except for the quantification of negative-strand HCV RNA, which was done at day 1 post inoculation. Indeed, at later time points multiple rounds of infection are expected to cause a bias in the assessment of viral genome replication per se if production of viral particles is affected.
Lipid analyses
The TAG mass was quantified using the PAP150TG kit (BioMérieux) as described in the online supplementary material. For analysis of lipid secretion capacity, cells were incubated for the last 24 hours of culture with oleic acid (0.6 mM) in complex with bovine serum albumin (oleic acid/BSA) containing 1 μCi/mL [1-14 C] oleic acid, then lipids were extracted from cells and media and fractionated by thin layer chromatography followed by quantification of radioactivity as described previously 28 and in the online supplementary material.
Statistical analyses
Results were expressed as the mean±SEM of at least three independent experiments. Statistical significance was evaluated using Student's t-test for unpaired two-sided data (*p<0.05, **p<0.01 and ***p<0.001) after a Shapiro-Wilk test was done to confirm that all data follow a normal distribution.
RESULTS

LPCAT1 is downregulated by HCV
As a starting point, we investigated whether HCV infection affects the expression of any member of the LPCAT family in Huh-7.5.1 cells (see online supplementary figure S1). Only LPCAT1 showed significantly reduced mRNA amounts upon JFH1-HCV inoculation (0.47±0.05), correlating with reduced LPCAT1 protein amounts as assessed by western blot analysis (0.61±0.09) ( figure 1A ). Most importantly, confocal microscopy analysis confirmed that at the single-cell level those cells that were actually infected upon HCV inoculation showed a clear decrease in LPCAT1 signal intensity compared with noninfected cells (figure 1B). We concluded that HCV infection induces downregulation of LPCAT1 expression occurring at least partly at the transcriptional level.
As approaches to unravelling mechanisms of HCV-induced downregulation of LPCAT1, we transfected Huh-7.5.1 cells with either a subgenomic JFH1-HCV replicon or a plasmid encoding JFH1-HCV core protein (figure 2). LPCAT1 expression was unchanged in cells harbouring the subgenomic replicon, suggesting that the downregulation observed upon HCV infection involves neither the virus non-structural proteins nor the viral genome replication step ( figure 2A, B) . By contrast, cells transfected with core-encoding plasmid had significantly reduced LPCAT1 mRNA amounts at the population level (figure 2C), and most strikingly at the single-cell level those cells that actually expressed HCV core protein had reduced LPCAT1 protein signal intensity ( figure 2D ). Thus, the sole expression of core protein was sufficient to recapitulate HCV infection-induced downregulation of LPCAT1.
LPCAT1 depletion increases production of HCV particles with high infectivity and low density Next we wanted to determine whether LPCAT1 downregulation has an impact on HCV infectious cycle. To address this question, we used a lentiviral vector encoding shRNA against LPCAT1 (shLPCAT1). In Huh-7.5.1 cells, this indeed resulted in a strong decrease of LPCAT1 protein and mRNA amounts (0.34±0.1 for both) compared with control cells treated with lentivirus encoding shRNA against luciferase (shLuc) (see online supplementary figure S2A, B) . This depletion was specific to LPCAT1 as the mRNA amount of LPCAT3, the main LPCAT in hepatocytes, 29 remained unchanged (see online supplementary figure S2C ). An even stronger decrease of LPCAT1 protein and mRNA amounts was observed in shLPCAT1-transduced Huh-7.5.1 cells that were inoculated with HCV (0.17±0.07 and 0.20±0.04, respectively), suggesting an additive effect of HCV infection and shLPCAT1 on LPCAT1 depletion (see online supplementary figure S2D-E). We also verified that shLPCAT1 transduction had no cytotoxic effect (see online supplementary figure S3A).
To examine the impact of LPCAT1 depletion on HCV infectious cycle, we first used an infectivity assay to evaluate the production of infectious virus in the culture supernatant. The infectivity titre was significantly increased in LPCAT1-depleted Huh-7.5.1 cells (5.84±2.08) (figure 3A). However, this effect could not be attributed to increased replication of viral genome because upon LPCAT1 depletion the amount of negative-strand HCV RNA was modified neither in these HCV-infected cells (figure 3A) nor in cells harbouring a subgenomic HCV replicon (see online supplementary figure S4). These results pointed to viral morphogenesis as the step of HCV infectious cycle affected by LPCAT1 depletion. Nevertheless, LPCAT1 depletion had only a slight, not significant tendency to increase the viral load, which reflects the production of physical viral particles irrespective of their infectivity. Accordingly, the specific infectivity (ratio of infectivity titre to viral load) was significantly increased in LPCAT1-depleted cells (3.83±1.69). To exclude putative offtarget effects of shLPCAT1, we transfected shLPCAT1-transduced Huh-7.5.1 cells with expression plasmids carrying wild-type or an shLPCAT1-resistant version of LPCAT1 gene (see online supplementary figure S5A), which led to increasing restoration of LPCAT1 protein expression (see online supplementary figure S5B ). This indeed restrained the shLPCAT1-induced gain in both infectivity titre and specific infectivity in a dosedependent manner (see online supplementary figure S5C), with a good linear inverse relationship between LPCAT1 protein amount and HCV infectivity titre (see online supplementary figure S5D ). Collectively, the data suggested that LPCAT1 depletion favours the morphogenesis of highly infectious virus.
Finally, because HCV infectivity is inversely correlated with the buoyant density of viral particles, 25 30 we subjected culture supernatants from HCV-infected Huh-7.5.1 cells depleted or not for LPCAT1 to isopycnic ultracentrifugation through iodixanol gradients (see a representative experiment in figure 3B-E).
As previously reported for HCV grown in Huh-7 cell line, 25 30 the majority of viral RNA peaked between 1.09 and 1.14 g/mL (figure 3B). However, LPCAT1 depletion led to a shift of HCV RNA towards fractions of lower buoyant density: the percentage of total viral load present below 1.08 g/mL was 22.60%±1.65% for LPCAT1-depleted cells compared with 12.59%±1.99% for control cells. The excess of highly infectious particles produced upon LPCAT1 depletion was also found in these fractions of lower density (figure 3C). We concluded that LPCAT1 depletion increases the production of HCV particles of high specific infectivity coinciding with low buoyant density.
LPCAT1 depletion leads to LD remodelling, increased TAG storage and increased secretion of TAG-rich lipoproteins
The lower buoyant density of HCV produced upon LPCAT1 depletion was consistent with a TAG enrichment of viral particles, prompting us to examine the impact of LPCAT1 depletion on the hepatocellular lipid metabolism. Confocal microscopy of Huh-7.5.1 cells labelled with BODIPY 493/503 did not show any gross modification of the intracellular LD distribution upon LPCAT1 depletion (figure 4A). However, the mean number of LDs was significantly reduced in LPCAT1-depleted cells compared with control cells (153.20±37.89 and 352.12±78.14 LDs/cell, respectively) (figure 4B). Furthermore, measurement of LD size showed a shift of the LD diameter distribution towards larger LDs upon LPCAT1 depletion (figure 4C). Besides these modifications that might reflect fusion of small LDs into larger ones, the net intracellular TAG amount was increased in the steady state in LPCAT1-depleted cells (1.72 ±0.07) (figure 4D). Because hepatic cells produce TAG-rich lipoproteins, this increased intracellular TAG content could result from inhibition of their secretion. Unexpectedly, however, the amount of ApoB, the constitutive apolipoprotein of TAG-rich lipoproteins, was increased in the culture supernatant cles. An impaired capacity to enrich lipoproteins with TAGs could also lead to an increased intracellular TAG content. To test this hypothesis, Huh-7.5.1 cells were challenged with oleic acid containing [1- 14 C] oleic acid as a tracer then radiolabelled PLs and TAGs were quantified in cells and media (figure 5). The intracellular amounts of newly synthesised PLs and TAGs were similar in LPCAT1-depleted and control cells, indicating similar uptake and lipid synthesis capacity. However, the secretion of newly synthesised TAGs was significantly, although slightly increased in LPCAT1-depleted cells (1.24-fold±0.15-fold) while PL secretion was not modified. This indicates that LPCAT1-depleted cells have a slightly higher TAG secretion capacity compared with control. We concluded that LPCAT1 depletion in Huh-7.5.1 cells results in an altered lipid metabolism characterised by LD remodelling, increased intracellular TAG content, increased ApoB-containing lipoprotein secretion and increased TAG secretion capacity.
Next we examined the impact of LPCAT1 depletion on the hepatocellular lipid metabolism in the context of HCV infection. For all characteristics studied, similar effects were observed in LPCAT1-depleted Huh-7.5.1 cells irrespective of whether they were infected or not. Indeed, in infected Huh-7.5.1 cells LPCAT1 depletion led to a reduction in the mean number of LDs accompanied by a shift of the LD diameter distribution towards larger LDs (figure 6A-C) and increased both the intracellular amount of TAGs and the amount of secreted ApoB ( figure 6D, E) . Upon isopycnic iodixanol gradient ultracentrifugation of culture supernatant of these cells, ApoB peaked at a higher buoyant density than the very low density (<1.006 g/mL) expected for VLDLs (figure 6F), consistent with the reported inability of the Huh-7 cell line to secrete genuine VLDLs. 25 Nevertheless, ApoB and ApoE, another important component of VLDLs, were both found in fractions with a density below 1.08 g/mL ( figure 6F, G) , that is, in the density range of the excess of highly infectious HCV particles produced upon LPCAT1 depletion ( figure 3D, E) . Taken together, the results suggest that LPCAT1 depletion increases the secretion of TAG-rich lipoproteins and HCV particles associated with TAG-rich lipoproteins.
Validation of data in physiologically relevant PHH
Huh-7 sublines provide a most convenient and efficient HCV culture system, yet differ significantly from normal, quiescent, highly differentiated human adult hepatocytes and especially do not fully reproduce VLDL biogenesis. 25 In order to validate the data in a pathophysiologically relevant model, we used our HCV culture system in PHH, which produce genuine VLDLs and HCV particles whose properties mimic those of infectious HCV produced in vivo. 25 We first sought to determine whether HCV infection downregulates LPCAT1 expression in PHH as is the case in Huh-7.5.1 cells. Because PHH are primary cells, the infectivity titres reached upon JFH1-HCV inoculation were generally lower than those obtained in Huh-7.5.1 cells and varied from one donor of hepatocytes to another. When viral titres were below 5.10 4 ffu/mL, LPCAT1 mRNA amounts did not appear to be modified in PHH inoculated with HCV compared with naive PHH (figure 7A). When higher titres were reached, however, a reduction of LPCAT1 mRNA amounts was observed, and a strong linear inverse relationship was found between LPCAT1 expression levels and HCV infectivity titres (figure 7B), consistent with the occurrence of HCV-induced transcriptional downregulation of LPCAT1 in PHH.
Next we investigated the impact of LPCAT1 depletion on HCV infectious cycle in PHH. For this, PHH were transfected with siRNA against LPCAT1 (siLPCAT1) versus GFP (siGFP), then inoculated with HCV. A significant decrease in LPCAT1 protein amount was observed in PHH transfected with siLPCAT1 compared with control (0.37±0.05) (see online supplementary figure S2F) in the absence of cytotoxic effect (see online supplementary figure S3B). LPCAT1 depletion in PHH had no impact on HCV genome replication but increased Figure 3 Lysophosphatidylcholine acyltransferase 1 (LPCAT1) depletion in Huh-7.5.1 cells increases production of HCV particles with high specific infectivity and low density. Cells were transduced with lentiviral vectors encoding shRNA against luciferase (shLuc) or shRNA against LPCAT1 (shLPCAT1), and inoculated with HCV 3 days later. (A) Cells were lysed at day 1 post inoculation for quantification of negative-strand HCV RNA, and culture supernatants were collected at day 3 post inoculation for determination of infectivity titre and viral load, then calculation of specific infectivity. The means±SEM of three to eight independent experiments performed in triplicate are shown. (B-E) Culture supernatants were subjected to isopycnic iodixanol gradient ultracentrifugation, and fractions were probed for (B) viral load, (C) specific infectivity, (D) ApoB and (E) ApoE. All graphs shown (B-E) are from the same representative experiment, and are aligned with one another (a dotted line has been placed at the density of 1.08 g/mL).
the infectivity titre by almost 1 log (9.27±5.60) (figure 7C), indicating an effect on virus morphogenesis. However, the viral load was not significantly modified, therefore the specific infectivity of viral particles produced was increased in LPCAT1-depleted PHH (7.87±5.14). Upon isopycnic iodixanol gradient ultracentrifugation, the proportion of viral RNA-containing particles with a buoyant density below 1.08 g/mL was greater for HCV grown in PHH than for HCV grown in Huh-7.5.1 cells (compare siGFP in figure 7D with shLuc in figure 3B ), as previously reported. 25 Nevertheless, a further shift of HCV RNA towards low buoyant density fractions was observed upon LPCAT1 depletion in PHH: the percentage of total viral load present below 1.09 g/mL was 47.01%±0.73% for LPCAT1-depleted cells compared with 35.91%±0.68% for control cells ( figure 7D ). These low-density fractions contained the excess of highly infectious particles produced upon LPCAT1 depletion (figure 7E), also coinciding with an excess of ApoB ( figure 7F) . Thus, in PHH as in Huh-7.5.1 cells but even more strikingly LPCAT1 depletion appeared to favour the morphogenesis of HCV particles of high specific infectivity correlating with low buoyant density.
DISCUSSION
The human hepatocyte is both the cell type specialised in the biogenesis of VLDLs, which permit export of TAGs into the circulation, and the primary replication site of HCV, which circulates in the form of TAG-rich LVPs. Using two cell-culture-based models of human hepatocytes, we have here identified LPCAT1 as a host cell factor downregulated upon HCV infection. Depletion of this PL-remodelling enzyme was further found to affect TAG metabolism, leading to increased intracellular TAG content and eventually increased capacity of TAG secretion in the form of ApoB-containing lipoproteins. In infected hepatocytes, this also resulted in increased production of HCV particles of lowest buoyant density, that is, enriched in TAGs, which are those of highest infectivity. Thus, LPCAT1 downregulation 14 C] oleic acid as a tracer. Lipids from cells and media were extracted and fractionated by thin layer chromatography, and radioactivity in triacylglycerols (TAGs) and phospholipids (PLs) was quantified. The means±SEM of three independent experiments performed in triplicate are shown.
by HCV appears as an original viral strategy to increase the virus specific infectivity. These data support the idea that HCV hijacks the hepatocellular lipid metabolism, which is devoted in particular to the efflux of TAGs in the form of VLDLs, for the benefit of LVP morphogenesis.
High-throughput profiling studies in the Huh-7/JFH1 model have suggested that HCV regulates the expression of host genes involved in a variety of hepatocellular processes, including liver lipid metabolism, at the transcriptional, translational and posttranslational levels. [31] [32] [33] [34] Our study reveals a decrease in the amounts of both LPCAT1 mRNA and protein in JFH1-infected Huh-7.5.1 cells, consistent with HCV-induced downregulation of LPCAT1 expression occurring at least partly at the transcriptional level. The PHH model is less suitable for such studies owing to lower levels of HCV infection and to the notorious autofluorescence of these cells that precludes in situ immunofluorescence analysis. 25 Our finding of a strong linear correlation between HCV infectivity titre and LPCAT1 mRNA amount is all the more striking in view of these limitations, supporting the occurrence of transcriptional downregulation of LPCAT1 by HCV in a pathophysiologically relevant model. Whereas LPCAT1 expression was unchanged in cells replicating an HCV subgenomic replicon, the sole expression of HCV core protein recapitulated the downregulation of LPCAT1 upon HCV infection. Although we cannot exclude an additional contribution of other HCV components, the virus core protein thus appears to play a major role in LPCAT1 downregulation. In fact, this is not surprising as this multifunctional protein has been reported to regulate the expression of many host genes aside from its role as a structural component of the virion. 35 36 Furthermore, expression of HCV core protein alone is sufficient to alter the LD-associated proteome in various cell models. 37 38 Interestingly, HCV-induced changes in LD composition may involve different molecular mechanisms, including displacing of LD-associated proteins owing to the own localisation of HCV core protein to LDs, as reported for adipose differentiationrelated protein, 39 and direct or indirect regulation of gene expression, as suggested here for LPCAT1.
In hepatic cells, an increased intracellular TAG content can result from increased fatty acid uptake, increased TAG synthesis, decreased fatty acid oxidation and/or decreased TAG-rich lipoprotein secretion. The latter mechanism cannot account for the increased intracellular TAG amount observed in LPCAT1-depleted cells because the secretion of newly synthesised TAGs was slightly increased in these cells. Another mechanism is suggested by the localisation of LPCAT1 to LDs. Like HCV core protein, 39 LPCAT1 may displace LD-associated proteins involved in lipid metabolism by its mere presence at the LD surface. 40 Furthermore, LPCAT1 is a PL-remodelling enzyme that catalyses the acylation of lysophosphatidylcholine into phosphatidylcholine, 21 41 the reverse reaction being performed by phospholipases A2 that may also be present at the LD surface. 20 Lysophosphatidylcholine and phosphatidylcholine have a different shape, and the alteration of the surface lipid composition may lead to changes in LD stability (eg, LD fusion, LD interaction with membranes) and in protein binding. 19 Theoretically, LPCAT1 depletion should lead to an increased amount of lysophosphatidylcholine at the LD surface, a situation that does not favour LD fusion. 19 In fact, we observed fewer LDs of larger size, which may reflect LD fusion, in agreement with Moessinger et al. 22 23 Nevertheless, the modification of the PL monolayer composition induced by LPCAT1 depletion probably initiates a reaction cascade that leads to impairment of protein interactions with the LD surface and further, possibly, with other organelles such as endoplasmic reticulum or mitochondria. Indeed, the trafficking of LD-associated proteins, including key enzymes of TAG metabolism, can be strongly modulated and the various mechanisms are only beginning to be understood as exemplified by recent reports. 16 42 43 Besides the association of HCV particles with TAG-rich lipoproteins, another clinical feature that links HCV infection with the host lipid metabolism is the high prevalence of liver steatosis, which is partly attributable to a direct viral effect. 1 44 LPCAT1 depletion was shown here to cause both an increase in the net intracellular TAG content, that is, steatosis, and an increase in the production of HCV particles associated with TAG-rich lipoproteins, thus illustrating a possible link between liver steatosis and LVP morphogenesis. However, HCV infection is not sufficient to induce steatosis in cell culture 45 and a variety of mechanisms have been suggested to account for HCV-induced steatosis, including inhibition of VLDL biogenesis which, unlike LPCAT1 downregulation, may explain the hypobetalipoproteinaemia frequently associated with liver steatosis in HCV-infected patients.
1-3 7 44 46 Thus, HCV-induced steatosis may only partially be accounted for by LPCAT1 downregulation. Furthermore, it remains uncertain whether steatosis per se has a role in LVP morphogenesis. The occurrence of liver steatosis in HCV-infected patients may simply represent the net result of the sum of perturbations of the host lipid metabolism that HCV induces primarily for the benefit of viral replication and LVP production added to non-viral steatogenic mechanisms of metabolic origin that can coexist to varying degrees in the same individual.
Upon LPCAT1 depletion in Huh-7.5.1 cells, we observed an increased intracellular TAG content, an increased ApoB secretion and a slight but significant increase in the capacity of secretion of newly synthesised TAGs, whereas a recent study reported no alteration of the total amount of lipids and a decreased secretion of both ApoB and lipids in LPCAT1-depleted Huh-7 cells. 23 This apparent discrepancy may be partly due to the different Huh-7 sublines but is more likely explained by the different experimental conditions used. Since ApoB is stabilised by lipids or otherwise degraded, 47 we cultured Huh-7.5.1 cells in medium supplemented with foetal calf serum, which contains lipids, and provided them with a physiological concentration of oleic acid (0.6 mM) to assess the TAG secretion capacity. By contrast, Moessinger et al 23 cultured Huh-7 cells in serum-free medium for 3 days before lipid and ApoB analysis, and incubated them with only trace amounts of radiolabelled fatty acids for TAG secretion analysis. Under these conditions, the paucity of lipids available may have precluded TAG synthesis, hence ApoB stabilisation by lipidation and eventually lipoprotein formation.
LVPs found both in the liver and in the circulating blood of HCV-infected patients contain ApoB, the non-exchangeable Apo essential for VLDL scaffolding, and exchangeable Apos including ApoE. 4 5 48 The presence of ApoB and ApoE in the density range of the excess of HCV particles produced upon LPCAT1 depletion is compatible with their physical association but does not provide direct evidence for this hypothesis. Whereas a large body of evidence has underlined the essential role of ApoE both in production and infectivity of HCV, the literature contains conflicting reports as to whether ApoB is incorporated into HCV particles produced from Huh-7 cells and is necessary for production of infectious virus. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] One possible source of discrepancies between published data may be the intrinsic inability of Huh-7 cell line to fully lipidate ApoB and hence secrete genuine VLDLs. 25 Our HCV culture system in PHH provides a more relevant model for readdressing these issues, yet the lower viral titres make it even more difficult to purify and characterise hybrid LVPs present within a large excess of non-viral lipoproteins. 6 8 25 Nevertheless, our identification of LPCAT1 depletion as a single mechanism that increases both VLDL and LVP secretion suggests that HCV usurps at least some of the mechanisms of VLDL biogenesis for LVP morphogenesis, even if ApoB per se is not incorporated into HCV particles.
HCV is a leading cause of chronic liver disease ranging from steatosis to cirrhosis and hepatocellular carcinoma. Treatment against HCV has entered a new era with the recent development of directly acting antivirals, yet these drugs have a prohibitive price, are intrinsically at risk for selection of resistant variants and may not cure a small proportion of hard-to-treat patients among whom those infected with genotype 3, the HCV genotype most clearly associated with virally induced steatosis. 44 59 By contrast, host-targeting agents with anti-HCV activity are expected to confer a high barrier to drug resistance and a pangenotypic coverage, and therefore may appear as a useful complement to virus-targeting agents in most difficult-to-treat patients. 60 The intimate link of HCV with the host lipid metabolism designates lipid-modulating agents as putative antivirals. 3 61 Depending on their mechanism of action, however, a potential side effect of drugs in this therapeutic class may be to aggravate hepatic steatosis. With this in mind, targeting the LPCAT1-regulated lipid metabolism pathway in the opposite direction to that usurped by HCV may represent an attractive therapeutic approach because it is expected to reduce not only the viral titre but also hepatic steatosis.
